iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of Concern
22.12.2021 14:18:00 EET | Business Wire | Press release
iXensor Co., Ltd. (6734.TWO)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005223/en/
iXensor's PixoTest COVID-19 Antigen Test effectively detects Omicron and other key variants of concern (Photo: Business Wire)
iXensor, the pioneer of mobile health, declares that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies.
In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control.
Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.
Although vaccines have become widely available, Omicron has a higher chance of causing breakthrough infections and fundamentally changing the landscape of the pandemic across the globe. Rapid tests that cannot detect the Omicron variant make for a worrying prospect because false-negative results could potentially lull people into a false sense of security.
The CEO of iXensor, Dr. Carson Chen, commented "Now more than ever, Omicron-detectable frequent testing remains a critical part of COVID-19 response to keep communities open, employees and students safe, and enable people to resume traveling with less fear."
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, diabetes, diabetes and cardiovascular diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005223/en/
Contact information
Media Contact
Spokesperson: Patrick Liao
Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-928-570-208
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Research Highlights How Readable AI Memories Can Unlock More Personalised, Privacy-conscious Consumer Experiences2.11.2026 10:52:00 EET | Press release
Human sales and customer representatives have institutional memories to serve clients: their preferences and choices. How can we build a memory mechanism for AI services to create similarly personalised experiences? Ant International’s research on this subject recently received the Senior Area Chair (SAC) Highlight Award from the Best Paper Committee at EMNLP 2026, a leading global AI conference. Why do we need “readable AI memory”? In this paper titled 'Text as a universal interface for transferable personalisation', we look into one fact: until now, AI memory of a user has usually been generated and stored as dense numerical code only the original system can interpret. Two long-standing problems with that: First, today's user profiles are "black boxes" — opaque code locked inside a single app, so activity in one service teaches nothing to another, and every product has to re-learn you from scratch. Second, profiles are welded to the model that created them, so they don't transfer whe
Car Connectivity Consortium Expands Focus on Digital Access for Two-Wheelers and Micromobility2.11.2026 10:00:00 EET | Press release
The Car Connectivity Consortium® (CCC), the global organization advancing interoperable connectivity between vehicles and devices, today highlighted its expanding work across the two-wheeler and micromobility markets ahead of EICMA 2026 in Milan, Italy. Through its Light Motor & Mobility Task Group (LMTG), CCC is bringing member companies together to address the distinct digital access needs of these markets and identify opportunities to advance standardization and interoperability. Key highlights of CCC's two-wheeler and micromobility work include: Addressing two-wheeler digital access needs: LMTG is examining requirements across motorcycles, scooters, e-bikes and other two- and three-wheeled vehicles. Exploring new applications for digital key technology: Member discussions include vehicle access and starting, access to vehicle components, and digital key sharing. Building broader industry participation: CCC will engage with manufacturers and technology companies at EICMA 2026 to dis
Liberis and Qred Complete Merger Following Regulatory Approval to Create Global SMB Financial Platform2.11.2026 10:00:00 EET | Press release
Liberis, a leading global embedded finance platform, and Qred, one of Europe’s foremost digital small business banks, today announced the completion of their merger, first announced in June 2026, following approval from the Swedish Financial Supervisory Authority (SFSA). The merger combines Qred’s regulated banking capability and direct relationships with small businesses with Liberis’s embedded finance technology and distribution through more than 30 partners, including Deliveroo, Vagaro and Nexi. The group serves more than 60,000 small businesses across 17 countries and has access to approximately 11.5 million addressable merchants. Qred’s deposit-funded banking model and direct customer relationships complement Liberis’s partner-led distribution. Together, the businesses bring two routes to small business finance: through a regulated bank and through platforms that businesses already use. The group’s ambition is to broaden the financial services available to small businesses and its
OpenGate Capital Completes the Acquisition of Maersk Training, the Global Safety Training and Gas Safety Services Business of Maersk2.11.2026 10:00:00 EET | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has completed the acquisition of Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Terms of the acquisition were not disclosed. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services and training. Through Maersk H2S Safety Services, the company provides specialized outsourced hydrogen sulphide and Health, Safety and Environment safety services for customers in high-risk operating environments. The H2S Safety Services team provides onsite supervision, monitoring and safety equipment maintenance where the safety of personnel and the protection of assets are critical. Through its training business, the company also delivers safety training, competency developmen
Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy2.11.2026 09:00:00 EET | Press release
Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which invests in startups working at the intersection of biology, data, and AI. Since joining Sofinnova in 2022, Nunez-Vicandi has played a key role in the development of the firm's Digital Medicine strategy and broader AI efforts. He helped shape key AI investment theses within the Digital Medicine Strategy and is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro. Javier has also recently led an investment that remains in stealth. Within Sofinnova's broader AI efforts, Javier co-led the project that created Sofia, Sofinnova's proprietary AI platform, which supports investments and scientific analysis. As part of this effort, Javier helped lead the firm's collaborations with AWS and NVIDI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom